Patents Assigned to UPPTHERA
  • Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1
    Patent number: 12403198
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Grant
    Filed: March 27, 2021
    Date of Patent: September 2, 2025
    Assignee: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND
    Publication number: 20250073218
    Abstract: The present invention relates to NLRP3 protein degradation inducing compounds. Specifically, the present invention provides a bifunctional compound in which an NLRP3 protein binding moiety and an E3 ubiquitin ligase binding moiety are connected by a chemical linker, a method for preparing the same, a method for degrading NLRP3 protein using the same, and the use for preventing or treating NLRP3 inflammasome-related diseases.
    Type: Application
    Filed: November 4, 2021
    Publication date: March 6, 2025
    Applicant: UPPTHERA
    Inventors: Soo Hee Ryu, Ji Hoon Ryu, Hwa Jin Lee, Im Suk Min, Han Kyu Lee, Jun Kyu Lee, Ji Su Lee, Su Youn Koh, Seong Hoon Kim
  • GPX4 PROTEIN DEGRADATION-INDUCING COMPOUND
    Publication number: 20240000951
    Abstract: The present invention relates to a GPX4 protein degradation-inducing compound. Specifically, the present invention provides a bifunctional compound in which a GPX4 protein-binding moiety and a CRBN E3 ubiquitin ligase-binding moiety are linked by a chemical linker, a method for preparing the same, a method for degrading a GPX4 protein using the same, and the use for preventing or treating GPX4-related diseases or ferroptosis-related diseases.
    Type: Application
    Filed: December 2, 2021
    Publication date: January 4, 2024
    Applicant: UPPTHERA
    Inventors: Soo Hee Ryu, Ji Hoon Ryu, Hwa Jin Lee, Im Suk Min, Han Kyu Lee, Young Jin Choi, Seong Hoon Kim
  • PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND
    Publication number: 20230372498
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: August 2, 2023
    Publication date: November 23, 2023
    Applicant: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • VANILLIN DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1
    Publication number: 20230203006
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: March 27, 2021
    Publication date: June 29, 2023
    Applicant: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1
    Publication number: 20230159515
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: March 27, 2021
    Publication date: May 25, 2023
    Applicant: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • PYRAZOLO QUINAZOLINE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1
    Publication number: 20230158158
    Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
    Type: Application
    Filed: March 27, 2021
    Publication date: May 25, 2023
    Applicant: UPPTHERA
    Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
  • Cell-penetrating cereblon recombinant fusion protein and use thereof
    Patent number: 11358992
    Abstract: The present invention relates to a novel cell-penetrating recombinant fusion protein including a peptide domain consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide domain consisting of the amino acid sequence of SEQ ID NO: 2. The novel cell-penetrating cereblon recombinant fusion protein according to the present invention may be usefully employed in the prevention or treatment of cereblon-related diseases.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: June 14, 2022
    Assignee: UPPTHERA
    Inventors: SooHee Ryu, Hwa Jin Lee, Seong Hoon Kim, Hyeong Seok Lee
  • Atorvastatin derived HMG-CoA reductase degradation inducing compound
    Patent number: 11066391
    Abstract: The present invention relates to bifunctional compounds that induce HMG-CoA reductase degradation, in which in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked. The present invention also relates to a preparation method of the compounds, a method for degrading HMG-CoA reductase using the compounds, and a composition for the prevention or treatment of HMG-CoA reductase-related diseases comprising the compounds.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: July 20, 2021
    Assignee: UPPTHERA
    Inventors: Soo Hee Ryu, Hwa Jin Lee, Seong Hoon Kim, Hye Guk Ryu, Eun Bin Lee